Compare Mesoblast Limited (MESO) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Prospect Capital Corporation — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Prospect Capital Corporation trades at $1.83 (market cap $984.89M). The key difference: Mesoblast Limited is the larger of the two by market cap, and Prospect Capital Corporation pays a 22.76% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Prospect Capital Corporation for 78 Days on average.
| MESO | PSEC | |
|---|---|---|
Market Cap | $1.81B | $984.89M |
Volume | 240,620 | 10,087,405 |
Sector | Health | Financials |
52-Week High | $20.96 | $3.05 |
52-Week Low | $13.19 | $1.82 |
Typical Hold Time | 14 Days | 78 Days |
Enterprise Value | $1.89B | $2.74B |
Dividend Yield | — | 22.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
PSEC trades at $1.82, down 0.55% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has beaten EPS estimates for the last three quarters, though revenue and net income were negative in 2025. Recent news highlights dividend declarations and management commentary on market opportunities, but financial performance shows volatility with a sharp revenue decline in 2025.
The outlook is mixed; a low P/B ratio of 0.34 suggests potential undervaluation, but negative cash flow and inconsistent profitability pose risks. Analyst sentiment is cautious with a majority Hold rating. Key opportunities include dividend yield and earnings beats, while risks involve financial instability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
